The vast majority of Roche’s oncology drugs with an orphan drug designation are expected to be blockbusters by 2025, including Perjeta (pertuzumab), Tecentriq (atezolizumab), Herceptin ...

For HER2-positive breast cancers, additions included pertuzumab, ado-trastuzumab emtansine, and neratinib. The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR ...

The rising trend in health and lifestyle related problems in the world warrants us to be well informed and health-conscious of the latest happenings in this field. Medindia offers a freely ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

The Amsler grid is a good test for people with Macular Degeneration. The Amsler grid tests the condition of the center of the retina or "macula" ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...